Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,981 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infections Clear all
Withdrawn Phase 4 Interventional

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

NCT02990312
View directory record Official record
Conditions
Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions
Sirolimus + Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 4:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

NCT00342602
View directory record Official record
Conditions
PML, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2009 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional Results available

Patch Study - Intervention for HIV Positive Smokers

NCT02982772
View directory record Official record
Conditions
Smoking Cessation, HIV
Interventions
Combination Therapy, Standard Care Intervention
Other
Lead sponsor
dr. maria miguez
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01797445
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

NCT00002257
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

NCT03149757
View directory record Official record
Conditions
HIV Infections
Interventions
YouTHrive, Information-only Control
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 24 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

NCT03651453
View directory record Official record
Conditions
HIV Infections, Substance Abuse
Interventions
Decision aid, Standard care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 11, 2026, 4:30 PM EDT
No Longer Available No phase listed Expanded access

Atazanavir for HIV Infected Individuals: An Early Access Program

NCT00046345
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir (BMS-232632)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
163
States / cities
Hobson City, Alabama • Anchorage, Alaska • Phoenix, Arizona + 158 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

NCT04983030
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Interventions
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Biological
Lead sponsor
Boris Juelg, MD PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467
View directory record Official record
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

NCT00002023
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 2 Interventional

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

NCT00000803
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 11, 2026, 4:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

NCT06183502
View directory record Official record
Conditions
Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions
Quantitative survey, HIV and STI testing, Qualitative Assessment
Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 11, 2026, 4:30 PM EDT
Terminated Phase 1 Interventional

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00006222
View directory record Official record
Conditions
Sarcoma
Interventions
cilengitide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Phase 4 Interventional Results available

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

NCT04636437
View directory record Official record
Conditions
HIV Infections
Interventions
Doravirine 100 Mg, Integrase strand transfer inhibitors, Tenofovir alafenamide/emtricitabine, tenofovir disproxil fumarate/emtricitabine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional

The Efficacy of the HIV/AIDS Symptom Management Manual

NCT00241202
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome
Interventions
Symptom Management Manual
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Oct 11, 2026, 4:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

NCT04050735
View directory record Official record
Conditions
HIV-1-infection, Alcohol Drinking
Interventions
Alcohol, ethyl, moderate dose, Placebo
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 11, 2026, 4:30 PM EDT